European Journal of Molecular & Clinical Medicine

Abstract

Convalescent plasma and dexamethasone may reduce mortality in patients with viral respiratory diseases,patients who are critically ill (who are on ventilatory support) and are currently being investigated in trials as potential therapy for coronavirus disease 2019 (COVID-19). The RECOVERY clinical trial ,however revealed that treatment with dexamethasone,a classic glucocorticoid and convalescent plasma has potentially improved the survival of critically ill patients an thus decreasing the detrimental effects.
In this review, the epidemiological studies of evaluating convalescent plasma or hyperimmune immunoglobulin and corticosteroids therapy for people with COVID-19 are included, irrespective of ‘study design’, ‘disease severity’, age, gender or ethnicity. Meta-analysis studies were taken into references for a systematic review. It includes populations with other coronavirus diseases ‘(severe acute respiratory syndrome (SARS) ‘or ‘Middle East respiratory syndrome (MERS)’ and studies evaluating standard immunoglobulin or other quantitative assays were excluded.
The information portals like ‘World Health Organization (WHO) COVID-19 and meta-analysis done from Global Research Database’, ‘MEDLINE’, ‘Web of science’ ‘Embase, Cochrane COVID-19 Study Register’, ‘ Centers for Disease Control and Prevention COVID-19 Research Article Database’, PubMed were taken for references and searched some clinical trial entries completed and ongoing studies till Aug 2020.